10 stories from 5 sources
Supporting Articles
Summary
DeepSeek has built an annualized revenue run rate of roughly $400 million to $500 million, largely from cloud API access to its AI models. The scale of revenue is bolstering plans to raise billions of dollars and pursue a public listing.
Why it matters
If the numbers hold, DeepSeek becomes a rare Chinese AI company with IPO-grade revenue, raising the bar for monetization across the AI startup market.
Summary
Ode with Anthropic is a joint venture built around deploying forward engineers into large companies to implement AI systems, aiming to replace slow, expensive consulting-style rollouts with smaller teams shipping production work. It is backed by Anthropic and major financial sponsors including Blackstone, Hellman & Friedman, and Goldman Sachs.
Why it matters
If AI implementation becomes a productized service, it could redirect billions in enterprise spend from traditional consulting to model-backed deployment teams.
Summary
Anthropic-backed Ode launched to help enterprises deploy AI by embedding forward-deployed engineers directly with customers. The bet is that services-heavy implementation, not just frontier models, will drive the next wave of enterprise AI value.
Why it matters
If implementation becomes the bottleneck, the winners will be the companies that ship working systems, not the ones with the best demos.
Summary
Mira Murati’s new AI startup, Thinking Machines, unveiled its first model and positioned it against incumbent frontier labs by borrowing techniques and product cues seen in leading Chinese AI systems. The company is coming off a $2bn raise last year that valued it at about $12bn.
Why it matters
A $12bn, ex-OpenAI contender adopting China-proven playbooks intensifies the global race to deliver cheaper, more usable frontier models.
A curated list of other prominent stories from this day.
Summary
Cyclops raised $20 million in Series A funding to build out stablecoin settlement rails for payments companies. It is pitching a single-partner, single-API integration for stablecoin settlement, pay-ins, payouts, and treasury optimization across global corridors.
Why it matters
If Cyclops becomes the default integration layer, stablecoin settlement could move from bespoke pilots to a standardized payments primitive for fintechs.
Summary
Rime raised a $24 million Series A as it scales AI systems for handling customer phone calls. The company says its technology now processes more than 100 million calls each month across multiple businesses.
Why it matters
At scale, voice automation can quickly reprice customer support economics and redirect enterprise spend from labor to software.
Summary
Emergent raised a $130 million Series C that values it at over $1 billion. The company reports a $120 million annualized revenue run rate and more than 200,000 paying customers for its AI coding products.
Why it matters
A revenue-backed unicorn in AI coding signals that the category is consolidating around companies that can convert usage into durable paid demand.
Summary
S&P Global made a strategic investment in SSImple. The deal positions the two companies to deepen commercial and product collaboration around SSImple's offering.
Why it matters
Strategic capital from S&P can turn a niche startup into default infrastructure for regulated enterprise workflows.
Summary
Float raised a €4.5 million Series A led by Chapters Group AG to expand its revenue-based financing for tech SMEs. The company positions the product as non-dilutive growth capital tied to recurring revenue performance.
Why it matters
If revenue-based financing keeps attracting equity backing, more startups will have a viable funding path when traditional VC is restrictive or overpriced.
Summary
A new biotech startup is pursuing an obesity drug strategy that does not target GLP-1, diverging from the dominant approach behind recent blockbuster weight loss drugs. The company is betting that an alternative mechanism can deliver meaningful weight loss or differentiated benefits where GLP-1 therapies fall short.
Why it matters
Obesity remains one of the largest drug markets, and credible non-GLP-1 mechanisms could reset competition, pricing power, and acquisition targets.
Make it yours
Pick your topics, set your cadence, and receive your personalized First Pass in your inbox. It’s that simple!